Price Alert

Zentalis Pharmaceuticals ... (ZNTL)

NASDAQ: ZNTL · Real-Time Price · USD

1.61

0.13 (8.78%)

At close: Aug 15, 2025, 12:21 PM

Zentalis Pharmaceuticals Statistics

Share Statistics

Zentalis Pharmaceuticals has 72.14M shares outstanding. The number of shares has increased by 1.19% in one year.

Shares Outstanding	72.14M
Shares Change (YoY)	1.19%
Shares Change (QoQ)	0.2%
Owned by Institutions (%)	59%
Shares Floating	56.51M
Failed to Deliver (FTD) Shares	1,911
FTD / Avg. Volume	0.2%

Short Selling Information

The latest short interest is 4.77M, so 6.62% of the outstanding shares have been sold short.

Short Interest	4.77M
Short % of Shares Out	6.62%
Short % of Float	8.27%
Short Ratio (days to cover)	4.34

Valuation Ratios

The PE ratio is -1.3 and the forward PE ratio is -0.66. Zentalis Pharmaceuticals's PEG ratio is 0.03.

PE Ratio	-1.3
Forward PE	-0.66
PS Ratio	3.19
Forward PS	47.2
PB Ratio	0.64
P/FCF Ratio	-1.26
PEG Ratio	0.03

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Zentalis Pharmaceuticals.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 7.32, with a Debt / Equity ratio of 0.12.

Current Ratio	7.32
Quick Ratio	7.32
Debt / Equity	0.12
Debt / EBITDA	-0.21
Debt / FCF	-0.23
Interest Coverage	0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$406.17K
Profits Per Employee	$-999.03K
Employee Count	166
Asset Turnover	0.16
Inventory Turnover	n/a

Taxes

Income Tax	177K
Effective Tax Rate	-0.11%

Stock Price Statistics

The stock price has increased by -53.64% in the last 52 weeks. The beta is 1.72, so Zentalis Pharmaceuticals's price volatility has been higher than the market average.

Beta	1.72
52-Week Price Change	-53.64%
50-Day Moving Average	1.37
200-Day Moving Average	2.08
Relative Strength Index (RSI)	55.01
Average Volume (20 Days)	939,441

Income Statement

In the last 12 months, Zentalis Pharmaceuticals had revenue of 67.42M and earned -165.84M in profits. Earnings per share was -2.33.

Revenue	67.42M
Gross Profit	67.42M
Operating Income	-191.19M
Net Income	-165.84M
EBITDA	-191.19M
EBIT	-187.46M
Earnings Per Share (EPS)	-2.33

Full Income Statement

Balance Sheet

The company has 33.9M in cash and 39.58M in debt, giving a net cash position of -5.68M.

Cash & Cash Equivalents	33.9M
Total Debt	39.58M
Net Cash	-5.68M
Retained Earnings	-1.05B
Total Assets	384.02M
Working Capital	293.45M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -170.86M and capital expenditures -221K, giving a free cash flow of -171.08M.

Operating Cash Flow	-170.86M
Capital Expenditures	-221K
Free Cash Flow	-171.08M
FCF Per Share	-2.41

Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of -283.57% and -245.96%.

Gross Margin	100%
Operating Margin	-283.57%
Pretax Margin	-245.74%
Profit Margin	-245.96%
EBITDA Margin	-283.57%
EBIT Margin	-283.57%
FCF Margin	-253.74%

Dividends & Yields

ZNTL does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for ZNTL is $5, which is 257.1% higher than the current price. The consensus rating is "Hold".

Price Target	$5
Price Target Difference	257.1%
Analyst Consensus	Hold
Analyst Count	6

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	-4.12
Piotroski F-Score	1